https://www.selleckchem.com/pr....oducts/indoximod-nlg
There are few recent studies on the use of 5-aminosalicylates (5-ASA) as therapy for Crohn's disease (CD) in routine clinical practice. The aim of this database investigation was to provide real-world evidence on 5-ASA use in CD. Patients with CD, aged ≥18 years when first prescribed 5-ASA (index date) and having received 5-ASA at any time between 01 January 2006 and 07 May 2018, were included for analysis. Outcomes included treatment patterns and resource use. Of 21,456 patients with CD, 9492 (44.2%) had been prescribed 5-AS
Like
Comment
Share
